Light Sciences Oncology files $86.25M IPO (BizJournals)
Light Sciences Oncology, a Snoqualmie cancer treatment company that was spun off from its parent last year, has filed plans for an $86.25 million initial public offering.

Cephalon, Inc. Provides Update on Regulatory Status of SPARLON(TM) (FinanzNachrichten)
FRAZER, Pa., April 24 /PRNewswire-FirstCall/ -- Cephalon, ( Nachrichten ) Inc. announced today that the United States Food and Drug Administration (FDA) has extended the action date for its review of the Supplemental New Drug Application for SPARLON(TM) (modafinil) Tablets [C-IV] for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents to August 22, 2006.